Market Research Logo

Antibacterial Therapeutics - High levels of Pipeline Innovation Focused on the Increasing Unmet Need Associated with Antibiotic Resistance

Antibacterial Therapeutics - High levels of Pipeline Innovation Focused on the Increasing Unmet Need Associated with Antibiotic Resistance

Summary


Antibacterial resistance is currently believed to be responsible for over 700,000 deaths each year. As antibiotic resistance increases, due to the overuse and misuse of antibiotics, the number of avoidable deaths is expected to increase, with one study predicting there will be 10 million deaths caused by bacteria resistant to antibiotics in 2050.

There are several techniques being utilized to combat the spread of antibiotic resistance, which range from combining antibiotics to increase efficacy to reducing the use antibiotics in both humans and livestock.

However, significantly reducing the number of deaths caused by antibacterial resistance will require the development of new antibacterials that target infections caused by the most deadly and antibiotic resistant bacteria while acting on targets not currently utilized by marketed products in order to avoid cross resistance.

Without the development of innovate antibacterial products the emergence and spread of antibiotic resistance will not only increase the number of avoidable deaths caused by the infection itself, it also has the potential to increase the risks associated with surgery, while putting additional pressure on already stretched healthcare providers, as treating drug-resistant infections is considerably more expensive than treating drug-susceptible infections.

This report examines the entire antibacterial therapy area with a particular focus on four key indications, methicillin resistant staphylococcus aureus (MRSA), sepsis, pneumonia and tuberculosis, which were selected due to their pipeline size, prevalence and level of unmet need.

Scope

  • The antibacterial pipeline is large, with 1,634 products in active development. Does current pipeline innovation hold the potential to affect the future antibacterial market?
  • The four key indications in the antibacterial pipeline are tuberculosis, pneumonia, MRSA and sepsis. How does the composition of each pipeline compare both in terms of first-in-class and non-first-in-class innovation.
  • There are 234 first-in-class products in the antibacterial pipeline. Which of these possess the greatest potential to improve disease outcome and be commercially successful, based on their target?
  • Analysis of strategic consolidations and deals revealed a high level of activity between 2006 and 2017.
  • A significant number of first-in-class products have been identified with no prior involvement in deals. How does deal frequency and value compare between target families and molecule types, and which first-in-class programs have not yet been involved in a licensing or co-development deal?
Reasons to buy
  • Appreciate the current clinical and commercial landscapes by considering disease symptoms, pathogenesis, etiology, co-morbidities and complications, epidemiology, diagnosis, prognosis and treatment options.
  • Visualize the composition of the antibacterial therapeutics market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market.
  • Analyze the antibacterial pipeline and stratify by stage of development, molecule type and molecular target.
  • Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, human first-in-class targets have been assessed and ranked according to clinical potential. Promising early-stage targets have been reviewed in greater detail.
  • Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals, which may represent potential investment opportunities.


  • Executive Summary
    • Robust Pipeline Aims to Address Unmet Needs
    • High level of Innovation in the Sepsis and Tuberculosis Pipelines.
    • Opportunities to obtain innovative first-in-class products remain.
  • The Case for Innovation
    • Table figure 1: Antibacterial Therapeutics, US, Innovation Trends in Product Approvals, 1987-2014
    • Growing Opportunities for Biologic Products
    • Diversification of Molecular Targets
    • Innovative First-in-Class Product Developments Remain Attractive
      • Table figure 2: Antibacterial Therapeutics. US. Sales Performance of First-in-Class and Non-First-in-Class Products Post Marketing Approval, 2006-2013
    • Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation
    • Sustained Innovation
    • Report Guidance
  • Clinical and Commercial Landscape
    • Therapy Area Overview
    • Symptoms
      • Pneumonia
      • MRSA
      • Sepsis
      • Tuberculosis
    • Diagnosis
      • Tuberculosis
      • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections
      • Pneumonia
      • Sepsis
        • Table Antibacterial Therapeutics, Quick-Sequential Oran Failure Assessment Test Criteria
        • Table Antibacterial Therapeutics, Glasgow Coma Scale
        • Table Antibacterial Therapeutics, Sequential Organ Failure Assessment score
      • Tuberculosis
      • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections
      • Pneumonia
      • Sepsis
    • Pathophysiology
      • Tuberculosis
      • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections
      • Pneumonia
      • Sepsis
    • Prognosis
      • Tuberculosis
      • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections
      • Pneumonia
      • Sepsis
    • Treatment Options
      • Cell-Wall Synthesis Inhibitors
    • Overview of Marketed Products within Antibacterial Therapies
      • Table figure 3 : Antibacterial Therapeutics, Global, Molecule Types and Molecular Targets of Marketed Products, 2017
  • Assessment of Pipeline Product Innovation
    • Overview
      • Table figure 4: Antibacterial Therapeutics, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area 2017
    • Antibacterial Pipeline by Phase, Molecule Type and Molecular Target
      • Antibacterial Pipeline Overall
        • Table figure 5:Antibacterial Therapeutics, Global, Pipeline Products by Stage of Development and Molecule Type, 2017
      • Key Antibacterial Indications
        • Table figure 6: Tuberculosis, Pneumonia, MRSA, and Sepsis, Global, Pipelines by Stage of Development, 2017
        • Table figure 7: Tuberculosis, Pneumonia, MRSA, and Sepsis, Global, Pipelines by Molecule Type, 2017
    • Pipeline by Molecular Target
      • Antibacterial Disease Overall
        • Table figure 8: Antibacterial Therapeutics, Global, Pipeline by Molecular Target, 2017
      • Key Antibacterial Indications
        • Table figure 9: Tuberculosis, Pneumonia, MRSA, Sepsis, Global, Pipelines by Molecular Target, 2017
    • Comparative Distribution of Programs between the Antibacterial Therapeutics Market and Pipeline by Therapeutic Target Family
      • Table figure 10: Molecular Target Category Comparison, Pipeline and Marketed Products, 2017
      • Table figure 11: Antibacterial Therapeutics, Global, Pipeline by Molecular Target Class, First-in-Class Status and Stage of Development, 2017
      • Table figure 12: Antibacterial Therapeutics Market, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Products by Stage of Development (%), 2017
      • Table figure 13: Antibacterial Therapeutics Market, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Products by Molecule Type (%), 2017
      • Table figure 14: Antibacterial Therapeutics Market, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Products by Molecular Target (%), 2017
      • Table figure 15: Antibacterial Therapeutics Market, Global, Ratio of First-in-Class Products to First-in-Class Targets by Stage of Development and Molecular Target, 2017
      • Table figure 16: Antibacterial Therapeutics, Global, First-in-Class Products in Pipeline (Part 1), 2017
  • Signaling Pathways, and First-in-Class Molecular Target Integration.
    • The Complexity of Signaling Networks in Antibacterial therapies
    • Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target Integration
    • First-in-Class Target Matrix Assessment
      • Table figure 23: Antibacterial Therapeutics, Global, First-in-class Human Targets, 2017
      • Sepsis
        • Table figure 24: Sepsis, Global, First-in-class Targets, 2017
      • MRSA
        • Table figure 25: MRSA, Global, First-in-class Targets, 2017
      • Pneumonia
        • Table figure 26: Pneumonia, Global, First-in-class Targets, 2017
      • Tuberculosis
        • Table figure 27: Tuberculosis, Global, First-in-class targets, 2017
  • First-in-Class Target and Pipeline Program Evaluation
    • Pipeline Programs that Target Monocyte Differentiation Antigen CD14
      • Table Antibacterial Therapeutics, Monocyte Differentiation Antigen CD14 as a Therapeutic Target, 2017
      • Table Pipeline Programs Targeting Monocyte Differentiation Antigen CD14
    • Pipeline Programs that Target Toll-Like Receptor 3
      • Table Antibacterial Therapeutics, Toll-Like Receptor 3 as a Therapeutic Target, 2017
      • Table Pipeline Programs Targeting Toll-Like Receptor 3
    • Pipeline Programs that Target Gelsolin
      • Table Antibacterial Therapeutics, Gelsolin as a Therapeutic Target, 2017
      • Table Pipeline Programs Targeting Gelsolin
    • Pipeline Programs that Target NACHT LRR and PYD Domains Containing Protein 3
      • Table Antibacterial Therapeutics NACHT LRR and PYD Domains Containing Protein 3 as a Therapeutic Target, 2017
      • Table Pipeline Programs Targeting NACHT LRR and PYD Domains Containing Protein 3
    • Pipeline Programs that Target Low-affinity immunoglobulin gamma Fc region receptor Iia (CD32a)
      • Table Antibacterial Therapeutics, Low-affinity immunoglobulin gamma Fc region receptor IIa as a Therapeutic Target, 2017
      • Table Pipeline Programs Targeting Low-affinity immunoglobulin gamma Fc region receptor IIa
    • Pipeline Programs that Target Triggering Receptor Expressed on Myeloid Cells 1
      • Table Antibacterial Therapeutics, Triggering Receptor Expressed on Myeloid Cells 1s as a Therapeutic Target, 2017
      • Table Pipeline Programs Targeting Triggering Receptor Expressed on Myeloid Cells 1
    • Pipeline Programs that Target Furin
      • Table Antibacterial Therapeutics, Furin as a Therapeutic Target, 2017
      • Table Pipeline Programs Targeting Furin
    • Pipeline Programs that Target Angiopoietin 2
      • Table Antibacterial Therapeutics, Angiopoietin 2as a Therapeutic Target, 2017
      • Table Pipeline Programs Targeting Angiopoietin 2
  • Deals and Strategic Consolidations
    • Industry-Wide First-in-Class Deals
      • Table figure 28: Antibacterial Therapeutics, Global, Licensing Deals by Stage of Development, 2006-2015
      • Table figure 29 :Pharmaceutical Industry, Global, Industry-Wide Licensing Deals by Deal Value, Upfront Payment Value, Stage of Development and First-in-Class Status ($m), 2006-2015
    • Licensing Deals
      • Deals by Region, Value and Year
        • Table figure 30: Antibacterial Therapeutics, Global, Licensing Deals by Region and Value, 2006-2017
      • Deals by Stage of Development and Value
        • Table figure 31: Antibacterial Therapeutics, Global, Licensing Deals by Stage and Value, 2006-2017
      • Deals by Molecule Type, Molecular Target and Value
        • Table figure 32: Antibacterial Therapeutics, Global, Licensing Deals by Molecular Target, 2006-2017
      • Table for Licensing Deals with a Disclosed Value
        • Table figure 33: Antibacterial Therapeutics, Licensing Deals with Disclosed Values, 2006-2017
    • Co-development Deals
      • Table figure 36: Antibacterial Therapeutics, Global, Co-development Deals by Region and Value, 2006-2017
      • Table figure 37: Antibacterial Therapeutics, Global, Co-development Deals by Stage and Value, 2006-2017
      • Table figure 38: Antibacterial Therapeutics, Global, Co-development Deals by Molecule Type, 2006-2017
      • Table for Co-Development Deals with a Disclosed Value
        • Table figure 39: Antibacterial Therapeutics, Global, Co-development Deals with Disclosed Values, 2006-2017
    • List of First-in-Class Pipeline Products with and without Prior Deal Involvement
      • Table figure 40: Antibacterial Therapeutics, Global, First-in-class Programs in Active Development Without Recorded Prior Deal Involvement, 2017
      • Table figure 44: Antibacterial Therapeutics, Global, First-in-class Programs in Active Development With Recorded Prior Deal Involvement, 2017
  • Appendix
    • References
    • Abbreviations
    • Disease List
      • Tuberculosis:
      • Pneumonia
      • MRSA
      • Sepsis:
    • Research Methodology
      • Data integrity
      • Innovative and meaningful analytical techniques and frameworks:
      • Evidence based analysis and insight:
    • Secondary Research
      • Market Analysis
      • Pipeline Analysis
      • First-in-Class Matrix Assessment
      • First-in-Class Target Profiles
      • Licensing and Co-Development Deals
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report